PubRank

Gaia Schiavon

Author PubWeight™ 42.23‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009 3.48
2 A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res 2012 2.95
3 Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell 2010 2.38
4 Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 2007 2.18
5 Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 2007 2.08
6 Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J Clin Oncol 2008 1.99
7 Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol 2012 1.75
8 Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One 2011 1.44
9 The biological properties of cetuximab. Crit Rev Oncol Hematol 2008 1.31
10 Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases. J Cell Physiol 2011 1.27
11 Noninvasive detection of HER2 amplification with plasma DNA digital PCR. Clin Cancer Res 2013 1.09
12 Status of adjuvant endocrine therapy for breast cancer. Breast Cancer Res 2014 1.07
13 Drug transporters and imatinib treatment: implications for clinical practice. Clin Cancer Res 2010 1.06
14 SDHA mutations in adult and pediatric wild-type gastrointestinal stromal tumors. Mod Pathol 2012 1.05
15 Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC). Curr Cancer Drug Targets 2011 0.94
16 Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV. Support Care Cancer 2012 0.90
17 Antiangiogenic properties of metronomic chemotherapy in breast cancer. Future Oncol 2007 0.90
18 Merlin/NF2 functions upstream of the nuclear E3 ubiquitin ligase CRL4DCAF1 to suppress oncogenic gene expression. Sci Signal 2011 0.89
19 Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients. Eur J Cancer 2012 0.86
20 Wide-spectrum characterization of trabectedin: biology, clinical activity and future perspectives. Pharmacogenomics 2010 0.84
21 Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients. Oncology 2005 0.84
22 Follow-up tests to detect recurrent disease: patient's reassurance or medical need? Breast 2013 0.83
23 Last generation of amino-bisphosphonates (N-BPs) and cancer angio-genesis: a new role for these drugs? Recent Pat Anticancer Drug Discov 2006 0.83
24 Interleukin 1beta-511T gene (IL1beta) polymorphism is correlated with gastric cancer in the Caucasian population: results from a meta-analysis. Oncol Rep 2008 0.82
25 Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options. Clin Sarcoma Res 2013 0.82
26 Evaluation of patient enrollment in oncology phase I clinical trials. Oncologist 2013 0.81
27 Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer. Nat Clin Pract Oncol 2008 0.81
28 Hormono-biological therapy in metastatic breast cancer: preclinical evidence, clinical studies and future directions. Expert Opin Biol Ther 2008 0.81
29 Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer. BMC Cancer 2006 0.79
30 Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience. Expert Opin Investig Drugs 2012 0.78
31 Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study. Cancer Chemother Pharmacol 2006 0.78
32 Predictive factors for response to chemotherapy in colorectal cancer patients. Crit Rev Oncol Hematol 2004 0.77
33 PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients. J Cell Physiol 2012 0.77
34 PML expression in soft tissue sarcoma: prognostic and predictive value in alkylating agents/antracycline-based first line therapy. J Cell Physiol 2012 0.77
35 Sequential chemotherapy with cisplatin, leucovorin, and 5-fluorouracil followed by docetaxel in previously untreated patients with metastatic gastric cancer: a phase II study. Gastric Cancer 2012 0.77
36 Treatment algorithms for hormone receptor-positive advanced breast cancer: going forward in endocrine therapy—overcoming resistance and introducing new agents. Am Soc Clin Oncol Educ Book 2013 0.76
37 New target agents in the treatment of colorectal cancer patients. Expert Opin Drug Discov 2007 0.75
38 The new era in the treatment of advanced colorectal cancer patients: the role of monoclonal antibodies. Expert Opin Emerg Drugs 2006 0.75